Lenacapavir HIV Prevention: Gilead’s Stra...

By João L. Carapinha

July 10, 2025

Gilead Sciences has finalized a strategic partnership with the Global Fund. The agreement aims to supply lenacapavir HIV prevention, a twice-yearly inject...
Revolutionizing Pediatric Care: Approval of Malaria Medicine for Newborns
Talquetamab Multiple Myeloma: Impact, Evidence, and Policy Considerations
Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study
BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhi...
AI Clinician in Pediatric ICU: A Review and HEOR Perspective
10-Year Health Plan: Transforming England’s NHS for the Future
EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030
Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical ...
The Value of Self-Care in Public Health: Insights and Implications for Europe
Pharma Ad Spending Trends: Insights from the Top 10 Drug Advertisers of 2024
Dutch Health Disruption: Reimagining Care with Social Entrepreneurship
Pharmaceutical Industry Europe: Key Insights and Future Challenges for 2025